Back to top

NBIX Maintained by BMO Capital -- Price Target Raised to $170

NBIX Maintained by BMO Capital -- Price Target Raised to $170

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Neurocrine Biosciences, Inc. (NBIX)